Allergan rebuffed in seeking offers to combat Valeant bid: report

Sun May 11, 2014 12:37pm EDT

Related Topics

(Reuters) - U.S. medical firm Allergan Inc (AGN.N) declined to comment on Sunday on a report that it has been seeking offers from rival companies to combat Valeant Pharmaceuticals International's (VRX.TO) $47 billion cash and share offer.

A spokeswoman for Allergan told Reuters on Sunday the company had no comment to make on whether it was seeking offers from other companies, following a report by Bloomberg that Allergan has so far been rebuffed by rival companies it has tried to interest in making an offer.

Allergan contacted both Sanofi SA (SASY.PA) and Johnson & Johnson (JNJ.N) after Valeant made its offer on April 22, Bloomberg said, as well as GlaxoSmithKline Plc (GSK.L) and Novartis AG (NOVN.VX).

(Reporting by Scott DiSavino; Editing by Greg Mahlich)